STOCK TITAN
  1. Home
  2. News
  3. THTX

Theratechnologies Inc. - THTX STOCK NEWS

Welcome to our dedicated news page for Theratechnologies (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theratechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theratechnologies's position in the market.

News
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
Rhea-AI Summary
Theratechnologies Inc. announces the resignation of Mr. Alain Trudeau from the Board of Directors and the Audit Committee. The Company plans to appoint a new independent director to ensure compliance with securities regulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
management
-
News
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
Rhea-AI Summary
Theratechnologies receives a refusal to file letter from the FDA for Trogarzo® IM administration, impacting their supplemental Biologics License Application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
-
News
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
Rhea-AI Summary
Theratechnologies Inc. reported a positive Adjusted EBITDA for Q4 2023, doubling from Q3 to $5 million, with a net loss of $2.8 million. The company achieved record quarterly revenue of $23.5 million and annual revenue of $81.8 million. Phase 1 trial for sudocetaxel zendusortide in ovarian cancer reached a milestone. Guidance for 2024 forecasts $87-90 million in revenue and $13-15 million EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
earnings
News
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
Rhea-AI Summary
Theratechnologies Inc. announces preclinical research results demonstrating the potential of sudocetaxel zendusortide in activating immune defense mechanisms and enhancing anti-PD-L1 immune-mediated tumor cell killing in triple-negative breast cancer. The publication highlights the superior tumor growth inhibition and immune cell infiltration compared to docetaxel in a murine tumor model, suggesting new avenues for combining immunotherapy with sudocetaxel zendusortide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
News
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Rhea-AI Summary
Theratechnologies Inc. completes enrollment of the first six participants in Part 3 of Phase 1 clinical trial for TH1902 in advanced ovarian cancer patients, marking a significant milestone for the company's oncology development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
clinical trial
-
News
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Rhea-AI Summary
Theratechnologies Inc. will report financial results and provide a business update for its fiscal 2023. They will also address the Complete Response Letter issued by the U.S. FDA for the F8 formulation of tesamorelin. The call will be hosted by Mr. Paul Lévesque, President and CEO, and other members of the management team. Participants are encouraged to join the call at least ten minutes in advance to secure access. Webcast and replay information is available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
earnings
News
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
Rhea-AI Summary
Theratechnologies Inc. received a Complete Response Letter (CRL) from the FDA for the F8 formulation of tesamorelin, related to chemistry, manufacturing, and controls (CMC) and immunogenicity risk. The CRL does not affect the commercial availability of EGRIFTA SV®, the F4 formulation of tesamorelin, currently the only approved medication in the U.S. for reducing excess abdominal fat in adults with HIV and lipodystrophy. The company plans to address the FDA's concerns and pursue approval for the newer formulation of tesamorelin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.95%
Tags
none
-
News
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
Rhea-AI Summary
Theratechnologies Inc. received correspondence from the FDA regarding the sBLA for the F8 formulation of tesamorelin. The FDA is continuing its review of the application past the PDUFA goal date of January 22, 2024. Further information will be provided in due course.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.03%
Tags
none
-
News
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
Rhea-AI Summary
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) files supplemental Biologics License Application for intramuscular method of administration for Trogarzo® (ibalizumab-uiyk) maintenance dose for treatment of heavily treatment-experienced adults with HIV, following recent FDA approval of IV push loading dose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.32%
Tags
none
News
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
Rhea-AI Summary
Theratechnologies Inc. (THTX) filed a preliminary short form base shelf prospectus with Canadian securities regulatory authorities and a shelf registration statement with the SEC, to restore its original financing capacity. The filings provide for potential offerings of up to US$100,000,000 of various securities over a 25-month period, aiming to take advantage of favorable market conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock THTX logo
Theratechnologies Inc.

Nasdaq:THTX

THTX Rankings

#4568 Ranked by Market Cap
#5441 Ranked by Stock Gains
N/A Ranked by Dividends

THTX Stock Data

65.29M
34.20M
6.29%
50.89%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.